1. In Vivo

The Battle For OGS

 
• By Hazel Dawson

Celltech's hostile bid for OGS may have scuppered the company's cosy merger plans with CAT. But OGS isn't giving in without a fight. And Celltech's offer may even prove beneficial to OGS shareholders, bumping up the firm's price-tag for CAT--or another suitor.

When Oxford GlycoSciences PLC (OGS) in January 2003 announced its proposed merger with compatriot Cambridge Antibody Technology Group PLC (CAT), it became the first European biotech to agree to an offer that valued it at less than the cash on its balance sheet. (See "CAT Merges for Money: Chooses Well-Dowered OGS," In Vivo Europe Rx, February 2003 Also see "CAT Merges for Money; Chooses Well-Dowered OGS" - In Vivo, 1 February, 2003. [See Deal].)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Rising Leaders 2025: Kevin Parker On Climbing Toward Breakthroughs In Biotech

 
• By Meredith Landry

Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.

UK Must Put Adoption On A Par With Innovation, AZ Tells BioWales Forum

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.